The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe

Mark Jit; Joke Bilcke; Marie Josée J. Mangen; Heini Salo; Hugues Melliez; William Edmunds; Yazdanpanah Yazdan; Philippe Beutels

doi:10.1016/j.vaccine.2009.08.030

The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe

Mark Jit^*, Joke Bilcke, Marie Josée J. Mangen, Heini Salo, Hugues Melliez, William Edmunds, Yazdanpanah Yazdan, Philippe Beutels

^*Corresponding author for this work

Public Health England

Research output: Contribution to journal › Article › peer-review

82 Citations (Scopus)

Abstract

Cost-effectiveness analyses are usually not directly comparable between countries because of differences in analytical and modelling assumptions. We investigated the cost-effectiveness of rotavirus vaccination in five European Union countries (Belgium, England and Wales, Finland, France and the Netherlands) using a single model, burden of disease estimates supplied by national public health agencies and a subset of common assumptions. Under base case assumptions (vaccination with Rotarix^®, 3% discount rate, health care provider perspective, no herd immunity and quality of life of one caregiver affected by a rotavirus episode) and a cost-effectiveness threshold of €30,000, vaccination is likely to be cost effective in Finland only. However, single changes to assumptions may make it cost effective in Belgium and the Netherlands. The estimated threshold price per dose for Rotarix^® (excluding administration costs) to be cost effective was €41 in Belgium, €28 in England and Wales, €51 in Finland, €36 in France and €46 in the Netherlands.

Original language	English
Pages (from-to)	6121-6128
Number of pages	8
Journal	Vaccine
Volume	27
Issue number	44
DOIs	https://doi.org/10.1016/j.vaccine.2009.08.030
Publication status	Published - 19 Oct 2009

Bibliographical note

Funding Information:
We thank Thierry van Effelterre (GSK Biologicals Belgium) for sharing results from his dynamic model of rotavirus vaccination in Belgium. This study formed part of POLYMOD, a European Commission project funded within the Sixth Framework Programme, Contract number: SSP22-CT-2004–502084. MJ was funded by the Policy Research Programme in the Department of Health, England (grant number 039/0031). WJE's partner works for GlaxoSmithKline. YY has received travel grants and honoraria for presentations at workshops and for consultancy from Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, Roche and Tibotec.

Keywords

Cost-effectiveness
Rotavirus
Vaccination

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2009.08.030

Cite this

@article{f74b2a995f994014903241f0f99d45b4,

title = "The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe",

abstract = "Cost-effectiveness analyses are usually not directly comparable between countries because of differences in analytical and modelling assumptions. We investigated the cost-effectiveness of rotavirus vaccination in five European Union countries (Belgium, England and Wales, Finland, France and the Netherlands) using a single model, burden of disease estimates supplied by national public health agencies and a subset of common assumptions. Under base case assumptions (vaccination with Rotarix{\textregistered}, 3% discount rate, health care provider perspective, no herd immunity and quality of life of one caregiver affected by a rotavirus episode) and a cost-effectiveness threshold of €30,000, vaccination is likely to be cost effective in Finland only. However, single changes to assumptions may make it cost effective in Belgium and the Netherlands. The estimated threshold price per dose for Rotarix{\textregistered} (excluding administration costs) to be cost effective was €41 in Belgium, €28 in England and Wales, €51 in Finland, €36 in France and €46 in the Netherlands.",

keywords = "Cost-effectiveness, Rotavirus, Vaccination",

author = "Mark Jit and Joke Bilcke and Mangen, {Marie Jos{\'e}e J.} and Heini Salo and Hugues Melliez and William Edmunds and Yazdanpanah Yazdan and Philippe Beutels",

note = "Funding Information: We thank Thierry van Effelterre (GSK Biologicals Belgium) for sharing results from his dynamic model of rotavirus vaccination in Belgium. This study formed part of POLYMOD, a European Commission project funded within the Sixth Framework Programme, Contract number: SSP22-CT-2004–502084. MJ was funded by the Policy Research Programme in the Department of Health, England (grant number 039/0031). WJE's partner works for GlaxoSmithKline. YY has received travel grants and honoraria for presentations at workshops and for consultancy from Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, Roche and Tibotec. ",

year = "2009",

month = oct,

day = "19",

doi = "10.1016/j.vaccine.2009.08.030",

language = "English",

volume = "27",

pages = "6121--6128",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "44",

}

The cost-effectiveness of rotavirus vaccination : Comparative analyses for five European countries and transferability in Europe. / Jit, Mark; Bilcke, Joke; Mangen, Marie Josée J.; Salo, Heini; Melliez, Hugues; Edmunds, William; Yazdan, Yazdanpanah; Beutels, Philippe.

In: Vaccine, Vol. 27, No. 44, 19.10.2009, p. 6121-6128.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The cost-effectiveness of rotavirus vaccination

T2 - Comparative analyses for five European countries and transferability in Europe

AU - Jit, Mark

AU - Bilcke, Joke

AU - Mangen, Marie Josée J.

AU - Salo, Heini

AU - Melliez, Hugues

AU - Edmunds, William

AU - Yazdan, Yazdanpanah

AU - Beutels, Philippe

N1 - Funding Information: We thank Thierry van Effelterre (GSK Biologicals Belgium) for sharing results from his dynamic model of rotavirus vaccination in Belgium. This study formed part of POLYMOD, a European Commission project funded within the Sixth Framework Programme, Contract number: SSP22-CT-2004–502084. MJ was funded by the Policy Research Programme in the Department of Health, England (grant number 039/0031). WJE's partner works for GlaxoSmithKline. YY has received travel grants and honoraria for presentations at workshops and for consultancy from Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, Roche and Tibotec.

PY - 2009/10/19

Y1 - 2009/10/19

N2 - Cost-effectiveness analyses are usually not directly comparable between countries because of differences in analytical and modelling assumptions. We investigated the cost-effectiveness of rotavirus vaccination in five European Union countries (Belgium, England and Wales, Finland, France and the Netherlands) using a single model, burden of disease estimates supplied by national public health agencies and a subset of common assumptions. Under base case assumptions (vaccination with Rotarix®, 3% discount rate, health care provider perspective, no herd immunity and quality of life of one caregiver affected by a rotavirus episode) and a cost-effectiveness threshold of €30,000, vaccination is likely to be cost effective in Finland only. However, single changes to assumptions may make it cost effective in Belgium and the Netherlands. The estimated threshold price per dose for Rotarix® (excluding administration costs) to be cost effective was €41 in Belgium, €28 in England and Wales, €51 in Finland, €36 in France and €46 in the Netherlands.

AB - Cost-effectiveness analyses are usually not directly comparable between countries because of differences in analytical and modelling assumptions. We investigated the cost-effectiveness of rotavirus vaccination in five European Union countries (Belgium, England and Wales, Finland, France and the Netherlands) using a single model, burden of disease estimates supplied by national public health agencies and a subset of common assumptions. Under base case assumptions (vaccination with Rotarix®, 3% discount rate, health care provider perspective, no herd immunity and quality of life of one caregiver affected by a rotavirus episode) and a cost-effectiveness threshold of €30,000, vaccination is likely to be cost effective in Finland only. However, single changes to assumptions may make it cost effective in Belgium and the Netherlands. The estimated threshold price per dose for Rotarix® (excluding administration costs) to be cost effective was €41 in Belgium, €28 in England and Wales, €51 in Finland, €36 in France and €46 in the Netherlands.

KW - Cost-effectiveness

KW - Rotavirus

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=70349786426&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.08.030

DO - 10.1016/j.vaccine.2009.08.030

M3 - Article

C2 - 19715781

AN - SCOPUS:70349786426

VL - 27

SP - 6121

EP - 6128

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 44

ER -

The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this